scholarly journals Papulopustular rosacea during nivolumab therapy of metastatic squamous cell esophageal carcinoma

2021 ◽  
Vol 27 (9) ◽  
Author(s):  
Nimrit K Gahoonia ◽  
Alexis E Carrington ◽  
Cindy J Chambers ◽  
Raja K Sivamani
Keyword(s):  
Esophageal Carcinoma ◽  
Squamous Cell

Phase II trial of vinorelbine in metastatic squamous cell esophageal carcinoma. European Organization for Research and Treatment of Cancer Gastrointestinal Treat Cancer Cooperative Group.

1996 ◽  
Vol 14 (1) ◽  
pp. 164-170 ◽  
Author(s):  
T Conroy ◽  
P L Etienne ◽  
A Adenis ◽  
D J Wagener ◽  
B Paillot ◽  
...  
Keyword(s):  
Esophageal Carcinoma ◽  
Squamous Cell ◽  
Response Rate ◽  
Single Agent ◽  
Active Agent ◽  
Dose Intensity ◽  
World Health ◽  
Who Grade ◽  
European Organization ◽  
Prior Chemotherapy

PURPOSE To evaluate the response rate and toxic effects of vinorelbine (VNB) administered as a single agent in metastatic squamous cell esophageal carcinoma. PATIENTS AND METHODS Forty-six eligible patients with measurable lesions were included and were stratified according to previous chemotherapy. Thirty patients without prior chemotherapy and 16 pretreated with cisplatin-based chemotherapy were assessable for toxicity and response. VNB was administered weekly as a 25-mg/m2 short intravenous (i.v.) infusion. RESULTS Six of 30 patients (20%) without prior chemotherapy achieved a partial response (PR) (95% confidence interval [CI], 8% to 39%). The median duration of response was 21 weeks (range, 17 to 28). One of 16 patients (6%) with prior chemotherapy had a complete response (CR) of 31 weeks' duration (95% CI, 0% to 30%). The overall response rate (World Health Organization [WHO] criteria) was 15% (CR, 2%; PR 13%; 95% CI, 6% to 29%). The median dose-intensity (DI) was 20 mg/m2/wk. VNB was well tolerated and zero instances of WHO grade 4 nonhematologic toxicity occurred. At least one episode of grade 3 or 4 granulocytopenia was seen in 59% of patients. A grade 2 or 3 infection occurred in 16% of patients, but no toxic deaths occurred. Other side effects were rare, and peripheral neurotoxicity has been minor (26% grade 1). CONCLUSION These data indicate that VNB is an active agent in metastatic esophageal squamous cell carcinoma. Given its excellent tolerance profile and low toxicity, further evaluation of VNB in combination therapy is warranted.

Long-term results of operation for 420 patients with early squamous cell esophageal carcinoma discovered by screening

2004 ◽  
Vol 77 (5) ◽  
pp. 1740-1744 ◽  
Author(s):  
Guo-Qing Wang ◽  
Guang-Gen Jiao ◽  
Fu-Bao Chang ◽  
Wei-Hong Fang ◽  
Jin-Xiang Song ◽  
...  
Keyword(s):  
Esophageal Carcinoma ◽  
Squamous Cell ◽  
Long Term Results

A meta-analysis on surgery with or without postoperative radiotherapy to treat squamous cell esophageal carcinoma

2020 ◽  
Vol 80 ◽  
pp. 184-191 ◽  
Author(s):  
Hao-Nan Lin ◽  
Long-Qi Chen ◽  
Qi-Xin Shang ◽  
Yong Yuan ◽  
Yu-Shang Yang
Keyword(s):  
Esophageal Carcinoma ◽  
Squamous Cell ◽  
Postoperative Radiotherapy ◽  
Meta Analysis

scholarly journals Mesothelin expression in esophageal adenocarcinoma and squamous cell carcinoma and its possible impact on future treatment strategies

2020 ◽  
Vol 12 ◽  
pp. 175883592091757
Author(s):  
Valeska Moentenich ◽  
Erdem Comut ◽  
Florian Gebauer ◽  
Armin Tuchscherer ◽  
Christiane Bruns ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Esophageal Carcinoma ◽  
Squamous Cell ◽  
Locally Advanced ◽  
Survival Rates ◽  
Treatment Strategies ◽  
High Expression ◽  
Esophageal Carcinomas ◽  
Mesothelin Expression ◽  
Low Expression

Background: Mesothelin is expressed at very low levels by normal mesothelial cells but is overexpressed in several human cancers. This makes mesothelin a promising target for immunotherapy. Limited data exist about mesothelin expression in esophageal carcinoma. In a current clinical trial, the highly potent anti-mesothelin antibody anetumab ravtansine is used in patients with mesothelin-positive tumors. Response rates are correlated with mesothelin expression (using the Ventana antibody) in tumor cells. No data are available on expression levels using the Ventana antibody. Most data have been generated using the Novocastra antibody. As patients are selected for clinical trials based on antibody staining of tumor samples, a comparison of these two available antibodies is crucial. Methods: We analyzed 481 esophageal carcinomas [373 esophageal adenocarcinomas (EACs), 108 esophageal squamous cell carcinomas (ESCCs)] using two different monoclonal antibodies (Novocastra and Ventana) for mesothelin expression (low–mid and high-level expression, as used in one clinical trial). We also checked for the correlation of these results with clinical and molecular data. Results: We revealed different staining results for both antibodies in EACs: Ventana: 53.6% (low expression: 25.3%; high expression: 28.3%) and Novocastra: 35.7% (low expression: 21.2%; high expression 14.5%). In ESCC we found comparable staining results: Ventana: 13.3% (low expression: 9.5%; high expression: 3.8%) and Novocastra: 13% (low expression: 11.1%; high expression: 1.9%). ARID1a-deficient EAC patients demonstrated significantly higher rates of mesothelin-positive tumors than ARID1a intact EAC patients. No correlations were found with other molecular alterations ( TP53 mutation, ERBB2 amplification) or survival rates. Conclusion: To the best of our knowledge, this is the largest study analyzing the importance of mesothelin expression in esophageal carcinoma. This study revealed a significant number of mesothelin-positive esophageal carcinomas, especially adenocarcinomas. New therapeutic targets are urgently required to improve the outcome of patients with locally advanced or metastasized esophageal carcinoma. The inhibition of mesothelin can be a new attractive target.

Abstract 3024: FGFR1 amplification is linked to the squamous cell carcinoma subtype in esophageal carcinoma.

2013 ◽  
Author(s):  
Katharina von Loga ◽  
Jule Kohlhaussen ◽  
Andreas H. Marx ◽  
Guido Sauter ◽  
Tobias Grob ◽  
...  
Keyword(s):  
Squamous Cell Carcinoma ◽  
Esophageal Carcinoma ◽  
Cell Carcinoma ◽  
Squamous Cell

scholarly journals Auraptene Attenuates Malignant Properties of Esophageal Stem-Like Cancer Cells

2016 ◽  
Vol 16 (4) ◽  
pp. 519-527 ◽  
Author(s):  
Saffiyeh Saboor-Maleki ◽  
Fatemeh B. Rassouli ◽  
Maryam M. Matin ◽  
Mehrdad Iranshahi
Keyword(s):  
Polymerase Chain Reaction ◽  
Squamous Cell Carcinoma ◽  
Esophageal Squamous Cell Carcinoma ◽  
Esophageal Carcinoma ◽  
Cell Carcinoma ◽  
Cancer Cells ◽  
Real Time ◽  
Squamous Cell ◽  
Chain Reaction ◽  
Polymerase Chain

The high incidence of esophageal squamous cell carcinoma has been reported in selected ethnic populations including North of Iran. Low survival rate of esophageal carcinoma is partially due to the presence of stem-like cancer cells with chemotherapy resistance. In the current study, we aimed to determine the effects of auraptene, an interesting dietary coumarin with various biological activities, on malignant properties of stem-like esophageal squamous cell carcinoma, in terms of sensitivity to anticancer drugs and expression of specific markers. To do so, the half maximal inhibitory concentration values of auraptene, cisplatin, paclitaxel, and 5-fluorouracil were determined on esophageal carcinoma cells (KYSE30 cell line). After administrating combinatorial treatments, including nontoxic concentrations of auraptene + cisplatin, paclitaxel, or 5-fluorouracil, sensitivity of cells to chemical drugs and also induced apoptosis were assessed. In addition, quantitative real-time polymerase chain reaction was used to study changes in the expression of tumor suppressor proteins 53 and 21 ( P53 and P21), cluster of differentiation 44 ( CD44), and B cell-specific Moloney murine leukemia virus integration site 1 ( BMI-1) upon treatments. Results of thiazolyl blue assay revealed that auraptene significantly ( P < .05) increased toxicity of cisplatin, paclitaxel, and 5-fluorouracil in KYSE30 cells, specifically 72 hours after treatment. Conducting an apoptosis assay using flow cytometry also confirmed the synergic effects of auraptene. Results of quantitative real-time polymerase chain reaction revealed significant ( P < .05) upregulation of P53 and P21 upon combinatorial treatments and also downregulation of CD44 and BMI-1 after auraptene administration. Current study provided evidence, for the first time, that auraptene attenuates the properties of esophageal stem-like cancer cells through enhancing sensitivity to chemical agents and reducing the expression of CD44 and BMI-1 markers.

Sign in / Sign up

Export Citation Format

Share Document